



# MEDICINES NOTIFICATION

## CLASS 4 MEDICINES DEFECT INFORMATION

### Caution in Use Pharmacy / Wholesaler Level

Date: 25 July 2024

EL (24)A/32

Our Ref: MDR 063-03/24

Dear Healthcare Professional,

### Aspen Pharma Trading Limited

Co-trimoxazole 80mg/400mg per 5ml adult suspension

PL 39699/0038

SNOMED Code 32280411000001100

Batch No	Expiry Date	Pack Size	First Distributed
B18324E	31 <sup>st</sup> May 2028	100ml	July 2024
B99324E	31 <sup>st</sup> May 2028	100ml	July 2024
B05924E	31 <sup>st</sup> May 2028	100ml	July 2024
B98724E	31 <sup>st</sup> May 2028	100ml	July 2024
B95224A	31 <sup>st</sup> January 2028	100ml	April 2024
B95324A	31 <sup>st</sup> January 2028	100ml	April 2024
B22823GA	31 <sup>st</sup> July 2027	100ml	September 2023
B85623F	30 <sup>th</sup> June 2027	100ml	July 2023
B01923C	31 <sup>st</sup> March 2027	100ml	May 2023
B55023B	28 <sup>th</sup> February 2027	100ml	March 2023
B55323B	28 <sup>th</sup> February 2027	100ml	March 2023
B97222L	31 <sup>st</sup> December 2026	100ml	January 2023
B27922I	30 <sup>th</sup> September 2026	100ml	November 2022
B60922G	31 <sup>st</sup> July 2026	100ml	August 2022
B02122E	31 <sup>st</sup> May 2026	100ml	June 2022
B71922D	30 <sup>th</sup> April 2026	100ml	May 2022
B40821K	30 <sup>th</sup> November 2025	100ml	February 2022
B82321F	30 <sup>th</sup> June 2025	100ml	July 2021
B77321F	30 <sup>th</sup> June 2025	100ml	July 2021
B21921D	30 <sup>th</sup> April 2025	100ml	May 2021
B96420I	30 <sup>th</sup> September 2024	100ml	November 2020
B71220H	31 <sup>st</sup> August 2024	100ml	September 2020

Active Pharmaceutical Ingredient: sulfamethoxazole, trimethoprim

#### Brief description of the problem

Aspen Pharma Trading Limited has informed the MHRA that an error has been found in the Patient Information Leaflet.

The error is in the section, 'What co-trimoxazole looks like and contents of the pack'. The PIL states '4001mg sulfamethoxazole' instead of '400 mg sulfamethoxazole'. The other sections of the PIL and product information state the correct strength.

#### Advice for healthcare professionals

Please continue to use the product as normal but be aware of the typographical error highlighted above.



# Medicines & Healthcare products Regulatory Agency

## **Advice for patients**

No further action is required by patients. Patients should continue to receive this medicine from these batches as given to you by your healthcare professional. There is no impact to product quality. If you have concerns about a medicine you may be using, please contact your healthcare professional.

Patients who experience adverse reactions or have any questions about the medication should seek medical attention. Any suspected adverse reactions should also be reported via the [MHRA Yellow Card scheme](#).

## **Further Information**

For medical information enquiries please contact: [Aspenmedinfo@professionalinformation.co.uk](mailto:Aspenmedinfo@professionalinformation.co.uk),  
Tel: 0800 008 7392

Yours faithfully

**Defective Medicines Report Centre**  
**10 South Colonnade**  
**Canary Wharf**  
**London**  
**E14 4PU**  
**Telephone +44 (0)20 3080 6574**  
[DMRC@mhra.gov.uk](mailto:DMRC@mhra.gov.uk)